This project aims to target the loss of the tumor suppressor TENT5C in multiple myeloma (MM). The primary goal is to investigate the effect of pathway-specific inhibitors in MM patients with biallelic TENT5C abnormalities. Additionally, the project seeks to identify novel synthetic lethality pathways associated with the loss of TENT5C in MM. Preliminary data suggest … Continued
This project aims to develop an optimized dual-targeted tandem VH-only fully-human CAR for the treatment of multiple myeloma, aiming to achieve durable remissions. Specific aims include analyzing factors associated with CAR T cell manufacturing success, predicting CAR T cell expansion post-infusion, correlating T cell composition with side effects, identifying markers for treatment response and resistance, … Continued
Acquired therapeutic resistance constitutes a major limitation to achieve a cure for multiple myeloma (MM). In this context, CAR T-cell and bispecific antibodies against BCMA and GPRC5D antigens have shown promising results, but most patients develop acquired resistance and eventually relapse. While acquired BCMA and GPRC5D inactivation leading to resistant disease has been reported following … Continued
The specific aims of this research focus on understanding the role of inflammatory mesenchymal stromal cells (iMSC) and bone marrow inflammation in multiple myeloma (MM) development and treatment response. Aim 1 aims to investigate the effect of novel treatments, including bispecific T cell engagers, on normalizing bone marrow inflammation and iMSC presence. Aim 2 seeks … Continued
This project aims to investigate the relationship between diet, microbiome composition, and response to standard-of-care treatment in newly diagnosed multiple myeloma (NDMM) patients. Stool samples from 150 NDMM patients will be analyzed alongside dietary data collected through interviews. These findings will be correlated with metabolome biomarkers using serum mass spectrometry. Patient-derived results will be validated … Continued
Chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough in cancer treatment and has achieved unprecedented success in hematologic malignancies. Recent advances in autologous CAR T-cell therapies utilize a patient’s own immune T cells, but “”off-the-shelf”” allogeneic CAR T cells have many potential advantages over autologous approaches, including immediate availability of cryopreserved batches, potential standardization … Continued
Autologous Stem Cell Transplantation represents a widely accessible therapy in Latin America, particularly crucial given the limited availability of new medications in the region, including monoclonal antibodies, next-generation proteasome inhibitors, immunomodulators, and advanced cellular therapies. This study aims to assess the impact of the genetic profile, particularly single nucleotide variants (SNVs), on the clinical outcomes … Continued
Multiple myeloma (MM) is a rare neoplastic disorder characterized by uncontrolled clonal proliferation of malignant plasma cells in the bone marrow (BM). In the last decade, the therapeutic approaches to treat MM patients have been improved. Nevertheless, the urgent need to identify new therapeutic targets remains to develop more effective strategies against this uncurable disease. … Continued
In this collaborative research project, we aim to identify and develop blood biomarkers improving MGUS follow-up. To achieve this, blood-based proteomic analysis using untargeted i3-D/LC mass spectrometry in unique prospective longitudinal blood samples (n=880) collected in participants of the Northern Sweden Health and Disease Study (UmeÃ¥ University, Sweden) is performed. Routine and novel biomarkers will … Continued
Copy Number Alterations (CNAs) play a key role in the Multiple Myeloma (MM) pathogenesis and prognostic stratification of the disease. For this reason, it is of particular biological and clinical interest to study the temporal occurrence of early alterations over the developmental history of MM. This, in order to identify specific altered chromosomal regions or … Continued
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
